Imiquimod-Induced Psoriasis Model Development Services
The development of effective therapies for psoriasis necessitates the use of reliable and representative disease models. The imiquimod (IMQ)-induced psoriasis model stands out as a pivotal tool in preclinical studies, offering a unique platform that closely mimics the complex pathology observed in human psoriasis. At Ace Therapeutics, we specialize in providing comprehensive IMQ-induced psoriasis model development services for our clients.
Introduction to IMQ-Induced Psoriasis Models
The IMQ-induced psoriasis mouse model leverages the potent toll-like receptor 7 (TLR7) agonist, imiquimod, to elicit a psoriatic phenotype in mice. Topical application of imiquimod to the skin triggers a cascade of events, including the upregulation of key cytokines, such as IL-17 and IL-23, which are central to the pathogenesis of psoriasis. This leads to the characteristic features of the disease, including erythema, scaling, epidermal hyperplasia, and dermal inflammation. This model replicates not only the skin pathology but also the systemic inflammation associated with the disease, making it an invaluable tool for studying disease mechanisms and therapeutic interventions.
Fig. 1 Optimization of Imiquimod (IMQ)-induced Psoriasis Model for Exhibiting Efficacy of Interleukin-17A Antibody on C57BL/6 Mice. (Li Q, et al., 2021)
Our IMQ-Induced Psoriasis Model Development Services
At Ace Therapeutics, we specialize in providing comprehensive IMQ-induced psoriasis model development services tailored to meet the diverse needs of our clients in the biopharmaceutical industry. Our services encompass a range of preclinical research solutions designed to facilitate the discovery and validation of potential antipsoriatic therapies.
- Establishment and Validation of IMQ-Induced Psoriasis Models
Ace Therapeutics offers comprehensive services to establish and validate the IMQ induced psoriasis model.
| Service Options | Description |
| Selection of Suitable Mouse Strains | We use specific strains that exhibit robust responses to imiquimod, ensuring reliable and reproducible results. |
| Psoriasis-like Model Induction | Our protocol involves applying a precise dose of imiquimod cream to the dorsal skin or ear of mice, typically over a period of 5-7 days. This induces psoriasis-like inflammation that mimics key pathological features of human psoriasis. |
| Psoriasis Model Validation | We employ the Psoriasis Activity and Severity Index (PASI) to quantify disease severity, assessing parameters such as erythema, scaling, and skin thickness. |
- Data Collection and Analysis
Our team at Ace Therapeutics is proficient in collecting and analyzing data to provide comprehensive insights into the efficacy of potential therapies.
| Service Options | Description |
| Histopathological Examination | Tissue samples are examined for epidermal thickness, keratinocyte proliferation, and immune cell infiltration. |
| Molecular and Immunological Assays | We conduct a range of assays, including qPCR, ELISA, and flow cytometry, to measure cytokine levels, gene expression, and immune cell populations. |
- Customized Study Design
Ace Therapeutics understands that each research project has unique requirements. We offer customized study designs to meet specific research objectives.
| Service Options | Description |
| Dose-Response Studies | Evaluating the efficacy of different doses of your therapeutic candidates to identify the optimal therapeutic window. |
| Mechanistic Studies | Investigating the underlying mechanisms of action of potential therapeutics using advanced molecular techniques. |
Our Advantages in IMQ-Induced Psoriasis Model Development
Ace Therapeutics boasts a team of highly skilled scientists with extensive experience in dermatological research and preclinical model development.
We provide end-to-end support throughout the research process, from initial study design to final data analysis.
Ace Therapeutics offers unparalleled flexibility in study design and execution. Our ability to customize services ensures that we can accommodate a wide range of research needs.
As a leading preclinical contract research organization (CRO), Ace Therapeutics is committed to supporting the advancement of psoriasis research through our specialized services for the IMQ induced psoriasis model. Our experienced team of biological experts and unwavering commitment to reproducibility and quality make us the trusted partner for companies and researchers seeking reliable and impactful preclinical data. For more information on our IMQ induced psoriasis model development services or to discuss how we can support your research, please do not hesitate to contact us.
Reference
- Li Q, et al. Application of imiquimod-induced murine psoriasis model in evaluating interleukin-17A antagonist. BMC Immunol. 2021;22(1):11.